BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34391932)

  • 1. Deficiency of GFRα1 promotes hepatocellular carcinoma progression but enhances oxaliplatin-mediated anti-tumor efficacy.
    Zhu H; Huang M; Luo J; Ji X; Liu Q
    Pharmacol Res; 2021 Oct; 172():105815. PubMed ID: 34391932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long noncoding RNA TINCR facilitates hepatocellular carcinoma progression and dampens chemosensitivity to oxaliplatin by regulating the miR-195-3p/ST6GAL1/NF-κB pathway.
    Mei J; Lin W; Li S; Tang Y; Ye Z; Lu L; Wen Y; Kan A; Zou J; Yu C; Wei W; Guo R
    J Exp Clin Cancer Res; 2022 Jan; 41(1):5. PubMed ID: 34980201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulated HOXC8 Expression Is Associated with Poor Prognosis and Oxaliplatin Resistance in Hepatocellular Carcinoma.
    Xu P; Zhang X; Ni W; Fan H; Xu J; Chen Y; Zhu J; Gu X; Yang L; Ni R; Chen B; Shi W
    Dig Dis Sci; 2015 Nov; 60(11):3351-63. PubMed ID: 26123838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
    Wang H; Xu H; Ma F; Zhan M; Yang X; Hua S; Li W; Li Y; Lu L
    Cell Death Dis; 2020 Apr; 11(4):225. PubMed ID: 32269215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long noncoding RNA CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by regulating HIF-1α activity and inhibiting epithelial-mesenchymal transition.
    Wang TH; Yu CC; Lin YS; Chen TC; Yeh CT; Liang KH; Shieh TM; Chen CY; Hsueh C
    Oncotarget; 2016 Jul; 7(28):43588-43603. PubMed ID: 27248828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin.
    Xiong W; Ren ZG; Qiu SJ; Sun HC; Wang L; Liu BB; Li QS; Zhang W; Zhu XD; Liu L; Wang WQ; Tang ZY
    BMC Cancer; 2010 May; 10():219. PubMed ID: 20487542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GFRα1 released by nerves enhances cancer cell perineural invasion through GDNF-RET signaling.
    He S; Chen CH; Chernichenko N; He S; Bakst RL; Barajas F; Deborde S; Allen PJ; Vakiani E; Yu Z; Wong RJ
    Proc Natl Acad Sci U S A; 2014 May; 111(19):E2008-17. PubMed ID: 24778213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.
    Huan HB; Yang DP; Wen XD; Chen XJ; Zhang L; Wu LL; Bie P; Xia F
    J Exp Clin Cancer Res; 2017 Jun; 36(1):86. PubMed ID: 28646927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulated UCA1 contributes to oxaliplatin resistance of hepatocellular carcinoma through inhibition of miR-138-5p and activation of AKT/mTOR signaling pathway.
    Huang G; Li L; Liang C; Yu F; Teng C; Pang Y; Wei T; Song J; Wang H; Liao X; Li Y; Yang J
    Pharmacol Res Perspect; 2021 Feb; 9(1):e00720. PubMed ID: 33565716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccinia-related kinase 1 promotes hepatocellular carcinoma by controlling the levels of cell cycle regulators associated with G1/S transition.
    Lee N; Kwon JH; Kim YB; Kim SH; Park SJ; Xu W; Jung HY; Kim KT; Wang HJ; Choi KY
    Oncotarget; 2015 Oct; 6(30):30130-48. PubMed ID: 26375549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback.
    Liu S; Bu X; Kan A; Luo L; Xu Y; Chen H; Lin X; Lai Z; Wen D; Huang L; Shi M
    Cancer Lett; 2022 Mar; 528():16-30. PubMed ID: 34958891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circular RNA circFBXO11 modulates hepatocellular carcinoma progress and oxaliplatin resistance through miR-605/FOXO3/ABCB1 axis.
    Li J; Qin X; Wu R; Wan L; Zhang L; Liu R
    J Cell Mol Med; 2020 May; 24(9):5152-5161. PubMed ID: 32222024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long non-coding RNA SBF2-AS1 promotes hepatocellular carcinoma progression through regulation of miR-140-5p-TGFBR1 pathway.
    Li Y; Liu G; Li X; Dong H; Xiao W; Lu S
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2826-2832. PubMed ID: 30115383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anti-tumor activities of Neferine on cell invasion and oxaliplatin sensitivity regulated by EMT via Snail signaling in hepatocellular carcinoma.
    Deng G; Zeng S; Ma J; Zhang Y; Qu Y; Han Y; Yin L; Cai C; Guo C; Shen H
    Sci Rep; 2017 Jan; 7():41616. PubMed ID: 28134289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
    Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
    J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA H19 promotes the development of hepatitis B related hepatocellular carcinoma through regulating microRNA-22 via EMT pathway.
    Li L; Han T; Liu K; Lei CG; Wang ZC; Shi GJ
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5392-5401. PubMed ID: 31298392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
    Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
    World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma.
    Ma J; Zeng S; Zhang Y; Deng G; Qu Y; Guo C; Yin L; Han Y; Cai C; Li Y; Wang G; Bonkovsky HL; Shen H
    Cancer Lett; 2017 Dec; 411():117-129. PubMed ID: 28987388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed cell death 10 promotes metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma via PP2Ac-mediated YAP activation.
    Sun B; Zhong FJ; Xu C; Li YM; Zhao YR; Cao MM; Yang LY
    Cell Death Dis; 2021 Sep; 12(9):849. PubMed ID: 34521817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.